GTG to pilot GeneType in Breast Screen centers across the U.S. - Seite 2

Increased Imaging Compliance: One of the primary outcomes of this study is to evaluate the impact of geneType on imaging compliance among at-risk populations. By exposing individualised breast cancer risks through the geneType Risk Assessment Test, patients are more likely to adhere to recommended screening protocols. The provision of personalised risk assessments should provide increased awareness among patients, motivating them to prioritise their breast health and adhere to scheduled appointments.

Implementation of GeneType: Collaborating with leading breast imaging centers will provide an excellent opportunity for integrating geneType in a high throughput clinical scenario. By fitting into these imaging center workflows, this study aims to validate the efficacy of geneType in identifying women at elevated risk of breast cancer and driving subsequent clinical imaging opportunities. This data will be important in driving broader adoption of risk assessments tests such as geneType to modify breast cancer screening and risk-reduction strategies.

Scalability and Expansion: Currently in the U.S., screening is between the ages of 40 and 74, therefore the current addressable market for geneType in this scenario is 68 million women. Recruiting these leading breast imaging centers as partners in the study provides a significant opportunity to showcase feasibility and efficacy of risk assessment application to the general population. This step serves as a template for GTG to achieve broader adoption and integration of geneType risk assessment into breast imaging practices. This not only extends the reach of personalised breast cancer risk assessment but supports the issue of breast density notification while ensuring that at-risk patients don’t fall under the radar.

Breast cancer risk assessment is crucial for ensuring quality care at breast centers of excellence. GeneType is revolutionising risk assessment beyond the current gold standard of care. Its integration into breast imaging centers marks a significant shift in how breast cancer risk is evaluated. By utilising risk assessment, institutions can tailor surveillance strategies, guide women into appropriate high-risk programs, increase patient awareness of their risk, promote shared decision-making, refine clinical actions regarding breast density notification, improve patient adherence, and pave the way for broader impact across populations. Ultimately, this study heralds a new era of precision medicine in the fight against breast cancer, providing screening and risk-reduction opportunities by identifying more at-risk individuals.